Loading clinical trials...
Loading clinical trials...
An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection
Conditions
Interventions
Interferon beta-1b
Ribavirin
Locations
1
Hong Kong
The University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong
Start Date
July 29, 2020
Primary Completion Date
July 1, 2022
Completion Date
August 1, 2022
Last Updated
July 31, 2020
NCT04525716
NCT03188796
NCT06355232
NCT05191420
NCT04611243
NCT04678193
Lead Sponsor
The University of Hong Kong
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions